- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07889349
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants
A Randomized, Double Blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Subcutaneous Administrations of SHR 3201 Injection in Healthy Participants
This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous administrations of SHR-3201.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Yifei He, PhD.
- Номер телефона: +86-0518-82342973
- Электронная почта: yifei.he.yh91@hengrui.com
Учебное резервное копирование контактов
- Имя: Yuanyuan Huang, PhD.
- Номер телефона: +86-0518-82342973
- Электронная почта: yuanyuan.huang@hengrui.com
Места учебы
-
-
Anhui
-
Hefei, Anhui, Китай, 230000
- Рекрутинг
- The First Affiliated Hospital of University of Science and Technology of China
-
Главный следователь:
- Jiong Shi
-
Главный следователь:
- Zhaoyi Yang
-
Контакт:
- Jiong Shi
- Электронная почта: jshi2022@ustc.edu.cn
-
Контакт:
- Zhaoyi Yang
- Номер телефона: +86-551-65997421
- Электронная почта: young2382@ustc.edu.cn
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Healthy male or female participants aged 18 to 60 years (inclusive) at the time of informed consent signing;
- Male participants weighing ≥ 50.0 kg, and female participants weighing ≥ 45.0 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²);
- Female participants of child bearing potential shall agree to contraception and oocyte donation avoidance from ICF signature to 6 months after last investigational product dose, with negative serum pregnancy tests at screening and baseline. Male participants shall agree to highly effective contraception and sperm donation avoidance from ICF signature to 6 months after last investigational product dose;
- Ability to understand the study procedures and requirements, willingness to participate voluntarily, and provide written informed consent.
Exclusion Criteria:
- Participants with past or current acute or chronic disorders of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric systems or metabolic abnormalities, as assessed by the Investigator to be unsuitable for study enrollment;
- Have a history of drug or other allergies, or, in the investigator's judgment, may be allergic to the investigational product or any of its components;
- Have undergone major surgery within 6 months prior to screening, or have undergone surgery that may significantly affect the in vivo disposition of the investigational product or the safety evaluation, or plan to undergo surgery during the trial period;
- Have participated in any clinical trial as a participant within 3 months prior to Screening, or plan to participate in other clinical trials during the course of this study;
- Have experienced blood loss or donated blood > 400 mL (excluding menstrual blood loss in females), received blood transfusion or blood products within 3 months prior to Screening, or plan to donate blood during the trial or within 1 month after the end of the trial;
- Cannot tolerate MRI or have MRI contraindications, including but not limited to cardiac pacemaker, defibrillator, artificial heart valve or other metallic implants; or other conditions assessed by the Investigator that may cause potential risks during MRI scanning;
- Have any laboratory abnormalities at screening, or have clinically significant abnormalities in vital signs, physical examinations, or laboratory tests specified in the protocol as judged by the investigator;
- Have chest X-ray (posteroanterior view) or abdominal ultrasound findings at Screening judged by the investigator to be clinically significant abnormalities;
- Have positive results at Screening for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), or Treponema pallidum antibody (Anti-TP);
- Have used or are currently using any prescription drugs or over-the-counter (OTC) medications within 2 weeks prior to dosing; or have taken functional vitamins, health supplements, or herbal products; or are known to require other medication during the trial period;
- Have consumed excessive amounts of tea, coffee, or caffeinated beverages (average > 8 cups per day, 200 mL per cup) within 3 months prior to screening;
- Have consumed special foods (e.g., grapefruit, grapefruit juice, or food/beverages containing grapefruit juice, chocolate, tobacco, alcohol, caffeinated products, etc.) within 48 hours prior to dosing;
- Have a history of regular alcohol consumption (i.e., > 14 standard units per week within 3 months prior to Screening, where 1 standard unit contains 14 g of alcohol, equivalent to 285 mL of beer, 25 mL of 40% spirit, or 85 mL of wine), or are unable to abstain from alcohol during the trial; or have a positive alcohol breath test;
- Have an average daily smoking history of > 5 cigarettes per day within 3 months prior to Screening, or are unable to abstain from smoking during the trial;
- Have a history of drug abuse or substance use; or have a positive result on drug abuse screening (including MDMA, methamphetamine, morphine, ketamine, and THC acid);
- Are pregnant or lactating females;
- Have difficulty with venous blood sampling, are unable to tolerate venipuncture, or have a history of needle or blood phobia;
- Participants who, in the opinion of the investigator, may be unable to complete the study for other reasons, or who are considered unsuitable for enrollment by the investigator.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Dose 1 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 1. |
SHR 3201 injection. SHR 3201 placebo. |
|
Экспериментальный: Dose 2 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 2. |
SHR 3201 injection. SHR 3201 placebo. |
|
Экспериментальный: Dose 3 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 3. |
SHR 3201 injection. SHR 3201 placebo. |
|
Экспериментальный: Dose 4 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 4. |
SHR 3201 injection. SHR 3201 placebo. |
|
Экспериментальный: Dose 5 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 5. |
SHR 3201 injection. SHR 3201 placebo. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Adverse events (AEs)
Временное ограничение: From pre-dose to 36 days post-dose.
|
From pre-dose to 36 days post-dose.
|
Вторичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
Serum concentration of SHR-3201 after single-dose administration
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Area Under the Concentration (AUC) of SHR-3201 after single administration (AUC0-last, AUC0-inf)
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Time to peak concentration (Tmax)
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Peak concentration (Cmax)
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Elimination half-life (T1/2)
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Clearance (CL)
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Steady-state volume of distribution (Vss)
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Bioavailability of SHR-3201 following subcutaneous administration
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Incidence of anti-drug antibodies (ADA)
Временное ограничение: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- SHR-3201-101
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .